Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Riluzole
Drug ID BADD_D01942
Description A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
Indications and Usage For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
Marketing Status approved; investigational
ATC Code N07XX02
DrugBank ID DB00740
KEGG ID D00775
MeSH ID D019782
PubChem ID 5070
TTD Drug ID D0H0KB
NDC Product Code 68462-381; 70510-2201; 42291-775; 0378-4145; 62756-538; 67877-286; 69076-200; 63278-1076; 65129-1011; 70515-700; 65977-0045; 66039-812
UNII 7LJ087RS6F
Synonyms Riluzole | 2-Amino-6-trifluoromethoxybenzothiazole | 2 Amino 6 trifluoromethoxybenzothiazole | Rilutek | RP-54274 | RP 54274 | RP54274 | PK-26124 | PK 26124 | PK26124
Chemical Information
Molecular Formula C8H5F3N2OS
CAS Registry Number 1744-22-5
SMILES C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005---
Discomfort08.01.08.003---
Disseminated intravascular coagulation01.01.02.002; 24.01.01.010--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.005383%
Drug interaction08.06.03.0010.001077%-
Dry mouth07.06.01.002--
Dysarthria17.02.08.001; 19.19.03.001--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.001615%
Dysphonia17.02.08.004; 19.19.03.002; 22.12.03.0060.000538%
Dyspnoea02.11.05.003; 22.02.01.004--
Dyspnoea exertional02.11.05.005; 22.02.01.0050.000538%-
Dysuria20.02.02.002--
Ear disorder04.03.01.001---
Ear pain04.03.01.003--
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002---
Eczema23.03.04.006--
Embolism venous24.01.01.0030.000538%-
Emphysema22.01.02.0020.001615%-
Endocrine disorder05.09.01.001---
Endophthalmitis06.04.05.009; 11.01.06.003--
Eosinophilia01.02.04.0010.001077%
Epistaxis22.04.03.001; 24.07.01.005--
Erythema multiforme10.01.03.015; 23.03.01.003--
Erythropenia01.07.02.001---
Euphoric mood19.04.02.006--
Exomphalos03.04.07.001; 07.16.03.002---
Extrapyramidal disorder17.01.02.007--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 14 Pages